Patents Assigned to Hokusan Co., Ltd.
-
Patent number: 11427620Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.Type: GrantFiled: September 4, 2017Date of Patent: August 30, 2022Assignees: Hokusan Co., Ltd., National Institute of Advanced Industrial Science and Technology, School Juridical Person The Kitasato InstituteInventors: Noriko Tabayashi, Toru Gotanda, Hanae Sasaki, Noriko Itchoda, Uiko Kagaya, Takeshi Matsumura, Akira Ito, Hiromi Ikadai
-
Publication number: 20210292382Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.Type: ApplicationFiled: September 4, 2017Publication date: September 23, 2021Applicants: Hokusan Co. Ltd., National Institute of Advanced Industrial Science and Technology, School Juridical Person The Kitasato InstituteInventors: Noriko Tabayashi, Toru Gotanda, Hanae Sasaki, Noriko Itchoda, Uiko Kagaya, Takeshi Matsumura, Akira Ito, Hiromi Ikadai
-
Patent number: 10799448Abstract: The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-? (IFN?) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFN? can give a sufficient effect even when administered in a very small amount.Type: GrantFiled: January 12, 2016Date of Patent: October 13, 2020Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, HOKUSAN CO. LTDInventors: Akira Ito, Takeshi Matsumura, Toru Gotanda, Noriko Tabayashi, Noriko Itchoda, Takashi Aoki, Uiko Kagaya
-
Publication number: 20190029953Abstract: The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-? (IFN?) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFN? can give a sufficient effect even when administered in a very small amount.Type: ApplicationFiled: January 12, 2016Publication date: January 31, 2019Applicants: National Institute of Advanced Industrial Science and Technology, Hokusan Co. LtdInventors: Akira Ito, Takeshi Matsumura, Toru Gotanda, Noriko Tabayashi, Noriko Itchoda, Takashi Aoki, Uiko Kagaya
-
Patent number: 9937271Abstract: The present invention provides an agent for controlling Escherichia coli diarrhea comprising a Shiga toxin as an active ingredient.Type: GrantFiled: November 25, 2014Date of Patent: April 10, 2018Assignees: IDEMITSU KOSAN CO., LTD., NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, HOKUSAN CO., LTD.Inventors: Kazutoshi Sawada, Takeshi Matsui, Eiji Takita, Takeshi Matsumura, Akira Ito, Noriko Tabayashi
-
Publication number: 20170173179Abstract: The present invention provides an agent for controlling Escherichia coli diarrhea comprising a Shiga toxin as an active ingredient.Type: ApplicationFiled: November 25, 2014Publication date: June 22, 2017Applicants: IDEMITSU KOSAN CO., LTD., NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, HOKUSAN CO. LTDInventors: Kazutoshi SAWADA, Takeshi MATSUI, Eiji TAKITA, Takeshi MATSUMURA, Akira ITO, Noriko TABAYASHI
-
Patent number: 9629900Abstract: The present invention provides oral compositions which contain interferon ? (IFN?) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFN? of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.Type: GrantFiled: February 24, 2015Date of Patent: April 25, 2017Assignees: Hokusan Co. Ltd., National Institute of Advanced Industrial Science and TechnologyInventors: Kuniaki Yoshioka, Ko Sato, Toru Gotanda, Akira Ito, Emiko Isogai, Kazuaki Takehara, Nobutoshi Maehara
-
Publication number: 20160015787Abstract: The present invention provides oral compositions which contain interferon ? (IFN?) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFN? of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.Type: ApplicationFiled: February 24, 2015Publication date: January 21, 2016Applicants: Hokusan Co. Ltd., National Institute of Advanced Industrial Science and TechnologyInventors: Kuniaki Yoshioka, Ko Sato, Toru Gotanda, Akira Ito, Emiko Isogai, Kazuaki Takehara, Nobutoshi Maehara
-
Patent number: 9181561Abstract: Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises a transformant capable of expressing adiponectin. Also specifically disclosed is a food composition for controlling appetite, which comprises the appetite control agent.Type: GrantFiled: January 18, 2010Date of Patent: November 10, 2015Assignees: Hokusan Co., Ltd., National Institute of Advanced Industrial Science and Technology, National University Corporation Hokkaido UniversityInventors: Takeshi Matsumura, Rie Yasuno, Chihiro Sugimoto, Noriko Tabayashi, Uiko Kagaya, Hiroko Miyashiro
-
Patent number: 8992905Abstract: The present invention provides oral compositions which contain interferon ? (IFN?) as an active ingredient for preventing and/or treating periodontal disease. The number of causative microorganisms of periodontal disease can be suppressed by administering the compositions into the oral cavity. IFN? of the present invention can produce a sufficient effect even when administered at a very low dose. Furthermore, the compositions of the present invention can also be readily administered to animals such as dogs by formulating them into feed or such.Type: GrantFiled: January 12, 2007Date of Patent: March 31, 2015Assignees: Hokusan Co. Ltd., National Institute of Advanced Industrial Science and TechnologyInventors: Kuniaki Yoshioka, Ko Sato, Toru Gotanda, Akira Ito, Emiko Isogai, Kazuaki Takehara, Nobutoshi Maehara
-
Patent number: 8710042Abstract: A method of reducing the contamination amount of mycotoxin in cereals wherein one or more compounds A selected from the group consisting of ammonium salts, primary to quaternary ammonium salts, alkali metal salts, alkaline earth metal salts and polyvalent metal salts of phosphorous acid and phosphite ester are given to the cereals.Type: GrantFiled: June 8, 2012Date of Patent: April 29, 2014Assignees: Mitsui Chemicals Agro, Inc., Hokusan Co. Ltd.Inventors: Daisuke Awakura, Kiyoshi Kimura, Kazuyoshi Masuda
-
Publication number: 20120237651Abstract: A method of reducing the contamination amount of mycotoxin in cereals wherein one or more compounds A selected from the group consisting of ammonium salts, primary to quaternary ammonium salts, alkali metal salts, alkaline earth metal salts and polyvalent metal salts of phosphorous acid and phosphite ester are given to the cereals.Type: ApplicationFiled: June 8, 2012Publication date: September 20, 2012Applicants: Hokusan Co., Ltd, Mitsui Chemicals Agro, Inc.Inventors: Daisuke Awakura, Kiyoshi Kimura, Kazuyoshi Masuda
-
Patent number: 8197832Abstract: We search for a cultivation method for reducing the amount of mycotoxin contamination in wheat which has been an important pending question for the quality in actual producing field of wheat and the health hazard risk for customers. The present invention discloses a method of reducing the contamination amount of mycotoxin in cereals characterized in that one or more compounds A selected from the group consisting of ammonium salts, primary to quaternary ammonium salts, alkali metal salts, alkaline earth metal salts and polyvalent metal salts of phosphorous acid and phosphite ester are given to the cereals.Type: GrantFiled: December 4, 2003Date of Patent: June 12, 2012Assignees: Mitsui Chemicals Agro, Inc., Hokusan Co., Ltd.Inventors: Daisuke Awakura, Kiyoshi Kimura, Kazuyoshi Masuda
-
Publication number: 20120115776Abstract: Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises a transformant capable of expressing adiponectin. Also specifically disclosed is a food composition for controlling appetite, which comprises the appetite control agent.Type: ApplicationFiled: January 18, 2010Publication date: May 10, 2012Applicants: National Institute of Advanced Industrial Science, National University Corporation Hokkaido Universit, Hokusan Co., Ltd.Inventors: Takeshi Matsumura, Rie Yasuno, Chihiro Sugimoto, Noriko Tabayashi, Uiko Kagaya, Hiroko Miyashiro